Combined heart and lung transplantation for unresectable primary cardiac sarcoma

Talbot, Susan; Taub, Robert N.; Keohan, Mary Lou; Edwards, Niloo M.; Galantowicz, Mark; Schulman, Larry L.

doi:10.1067/mtc.2002.126495

Cited by 72 publications

(59 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The data regarding cardiac sarcoma and outcome post-Tx are scarce and are not conclusive regarding the feasibility of cardiac Tx as a treatment option. 8,9 Emerging experimental and clinical short-term data have demonstrated anti-neoplastic properties of proliferation signal inhibitors. 20,21 However, only 1 patient was treated with proliferation signal inhibitors in our cohort, from which we cannot draw any conclusion.…”

Section: Discussionmentioning

confidence: 99%

“…4,5 Only small series with short observation times and without detailed analysis of the importance of the duration of pre-operative cancer-free interval have been published. [6][7][8][9][10][11][12] Hence, our aim was to investigate the influence of pre-Tx malignancy on post-Tx recurrence and long-term survival, focusing on preoperative cancer-free intervals in lung and heart Tx recipients.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Long-term follow-up of lung and heart transplant recipients with pre-transplant malignancies

Sigurdardottir

Bjørtuft

Eiskjær

et al. 2012

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Long-term follow-up of lung and heart transplant recipients with pre-transplant malignancies

Sigurdardottir

Bjørtuft

Eiskjær

et al. 2012

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

“…Talbot et al [93] investigated the role of combined heart and lung resection followed by en bloc heart and bilateral lung transplant, in four patients where the sarcoma extended beyond the cardiac borders of cardiectomy. All patients had neoadjuvant chemotherapy.…”

Section: Heart and Lung Transplantationmentioning

confidence: 99%

Primary cardiac sarcoma

Shanmugam¹

2006

European Journal of Cardio-Thoracic Surgery

132

157

View full text Add to dashboard Cite

Primary malignant lesions of the heart are rare. Although myxomas have been extensively described, there is a paucity of large studies on non-myxomatous cardiac tumours. On the other hand, there are several case reports on specific histopathological variants, in small numbers. Consequently there exists no consensus on therapeutic modalities for cardiac sarcomas. The prognosis for these lesions remains dismal, despite the enhanced diagnostic ability of newer technology. The reasons for the dismal prognosis are (1) the advanced tumour stage at presentation, (2) non-specific symptomatolgy, (3) insufficient awareness of these lesions, due to their rarity, (4) delayed diagnosis and/or misdiagnosis, which leads to (5) advanced tumour stage at presentation. Thus a vicious cycle is created. This article addresses these issues, deals with the surgically relevant modes of presentation, rather than the histopathology, and reviews the diagnosis and management options for the various sarcomas, categorized by the site and extent of cardiac involvement. Clinicians should be familiar with the presentation of these tumours and have a high index of suspicion, since the potential for long-term survival following resection does exist. Wide surgical resection remains the cornerstone of sarcoma therapy. Complete characterization of tumour extent using echocardiography and CT/MRI is mandatory to achieve this goal. Radical resections such as 'bench surgery' and transplantation may reduce local recurrence, but the risk of metastatic disease remains. The clinical experience with such approaches is limited. The role of adjuvant therapy is not yet established. In no other field of cardiac surgery would a multidisciplinary approach be more useful, in achieving cure or long-term palliation.

show abstract

“…Diagnosis with EBUS has the advantage of facilitating neoadjuvant therapy and hence reserving surgery for therapeutic purposes as the final step in multimodality treatment. Cardiac transplantation is another feasible therapeutic modality, but this approach would be disappointing due to local recurrence or metastases [13]. …”

Section: Discussionmentioning

confidence: 99%

Endobronchial Ultrasound Bronchoscopy to the Heart of the Matter

2016

View full text Add to dashboard Cite

Endobronchial ultrasound has been one of the success stories of the last decade, and the utility of the procedure continues to expand. Originally, it was developed for the staging and diagnosis of lung cancer, but its use rapidly expanded to other malignancies and even benign disease. We present the case of a patient originally referred with suspected endocarditis who was found to have a mass involving the right ventricle and the pulmonary outflow tract. Endobronchial ultrasound-guided biopsy was used to obtain a tissue diagnosis from the cardiac mass.

show abstract

Combined heart and lung transplantation for unresectable primary cardiac sarcoma

Abstract: Combined heart and lung transplantation is a technically feasible treatment for highly selected patients with localized advanced primary cardiac sarcomas. The high incidence of metastatic disease, however, limits its utility.

Cited by 72 publications

References 18 publications

Long-term follow-up of lung and heart transplant recipients with pre-transplant malignancies

Long-term follow-up of lung and heart transplant recipients with pre-transplant malignancies

Primary cardiac sarcoma

Endobronchial Ultrasound Bronchoscopy to the Heart of the Matter

Contact Info

Product

Resources

About